GenVec Announces Research on Improved Vaccine Vectors
GAITHERSBURG, Md., April 6, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response. The paper has been published online in PloS ONE, and can be accessed at http://dx.plos.org/10.1371/journal.pone.0033920. The article titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses" is an example of GenVec's proprietary vaccine technology.
"This paper describes one of several new tools we are using to generate better vaccines," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research. "This approach alters key elements of the vector so that a good vaccine response is generated even if an individual was previously exposed to an adenovirus. This technology expands our genetic vaccine toolbox used to create superior vaccines."
About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business
performance, conditions or strategies and other financial and
business matters, including expectations regarding funding, grants,
collaborations, revenues, cash burn rates, the development of
products and the success of the collaboration with Novartis, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act. GenVec cautions that these
forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Factors that may
cause actual results to differ materially from the results
discussed in the forward-looking statements or historical
experience include risks and uncertainties, including the failure
by GenVec to secure and maintain relationships with collaborators;
risks relating to the early stage of GenVec's product candidates
under development; uncertainties relating to research and
development activities; risks relating to the commercialization, if
any, of GenVec's proposed product candidates; dependence on the
efforts of collaborators and third parties; dependence on
intellectual property; and risks that we may lack the financial
resources and access to capital to fund our operations. Further
information on the factors and risks that could affect GenVec's
business, financial conditions and results of operations, are
contained in GenVec's filings with the U.S. Securities and Exchange
Commission (SEC), which are available at www.sec.gov. These forward looking
statements speak only as of the date of this press release, and
GenVec assumes no duty to update forward-looking statements.
Retail Investor and Media Contact:
GenVec, Inc.
Douglas J. Swirsky
(240) 632-5510
dswirsky@genvec.com
Institutional Investor Contact:
S.A. Noonan Communications
Susan A. Noonan
(212) 966-3650
SOURCE GenVec, Inc.
Web Site: http://www.genvec.com
Posted: April 2012
